Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma.

[1]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[3]  John M. Kirkwood,et al.  Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-α2b , 2007, Clinical Cancer Research.

[4]  D. Accapezzato,et al.  IFN‐α‐conditioned dendritic cells are highly efficient in inducing cross‐priming CD8+ T cells against exogenous viral antigens , 2006, European journal of immunology.

[5]  T. Bieber,et al.  Type I interferon‐associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis , 2006, Clinical and experimental dermatology.

[6]  T. Di Pucchio,et al.  Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. , 2006, Cancer research.

[7]  J. Kirkwood,et al.  Strategies for the Development of More Effective Adjuvant Therapy of Melanoma: Current and Future Explorations of Antibodies, Cytokines, Vaccines, and Combinations , 2006, Clinical Cancer Research.

[8]  G. Trinchieri,et al.  Virus overrides the propensity of human CD40L‐activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN‐γ and Th1 chemokine production , 2005, Journal of leukocyte biology.

[9]  T. Bieber,et al.  Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. , 2005, American journal of clinical pathology.

[10]  J. Clot,et al.  The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon‐α treatment , 2005, The British journal of dermatology.

[11]  Marlene Wolf,et al.  Chemokines: multiple levels of leukocyte migration control. , 2004, Trends in immunology.

[12]  I. Kerr,et al.  Differential Responses to IFN-α Subtypes in Human T Cells and Dendritic Cells 12 , 2003, The Journal of Immunology.

[13]  D. Olive,et al.  IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. , 2003, Journal of immunology.

[14]  V. Sondak,et al.  Pros and cons of adjuvant interferon in the treatment of melanoma. , 2003, The oncologist.

[15]  T. Di Pucchio,et al.  Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-α , 2003, The Journal of experimental medicine.

[16]  M. Colonna,et al.  Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas , 2003, The Journal of pathology.

[17]  F. Belardelli,et al.  Monocyte-Derived Dendritic Cells Generated After a Short-Term Culture with IFN-α and Granulocyte-Macrophage Colony-Stimulating Factor Stimulate a Potent Epstein-Barr Virus-Specific CD8+ T Cell Response1 , 2003, The Journal of Immunology.

[18]  A. Krieg,et al.  CpG-A-Induced Monocyte IFN-γ-Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN-α1 , 2003, The Journal of Immunology.

[19]  R. Kastelein,et al.  Novel IL-12 family members shed light on the orchestration of Th1 responses , 2003, Trends in Immunology.

[20]  K. Schäkel,et al.  The CD16+ (FcγRIII+) Subset of Human Monocytes Preferentially Becomes Migratory Dendritic Cells in a Model Tissue Setting , 2002, The Journal of experimental medicine.

[21]  D. Robinson,et al.  Further checkpoints in Th1 development. , 2002, Immunity.

[22]  T. Mcclanahan,et al.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. , 2002, Immunity.

[23]  M. Dziejman,et al.  IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.

[24]  M. Gilliet,et al.  Generation of Human CD8 T Regulatory Cells by CD40 Ligand–activated Plasmacytoid Dendritic Cells , 2002, The Journal of experimental medicine.

[25]  D. Olive,et al.  Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. , 2001, Blood.

[26]  G. Sanchez-Schmitz,et al.  CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. , 2001, International immunology.

[27]  Virginia Pascual,et al.  Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus , 2001, Science.

[28]  T. Di Pucchio,et al.  Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. , 2001, Blood.

[29]  P. Baeuerle,et al.  Phenotype and function of human dendritic cells derived from M‐DC8+ monocytes , 2001, European journal of immunology.

[30]  S. Miltenyi,et al.  BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.

[31]  T. Curiel,et al.  Macrophage-Derived Dendritic Cells Have Strong Th1-Polarizing Potential Mediated by β-Chemokines Rather Than IL-121 , 2000, The Journal of Immunology.

[32]  T. Di Pucchio,et al.  Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice , 2000, The Journal of experimental medicine.

[33]  D. Jarrossay,et al.  Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon , 1999, Nature Medicine.

[34]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[35]  H. Tilg,et al.  Interferon-β1b augments activation-induced T-cell death in multiple sclerosis patients , 1999, The Lancet.

[36]  N. Kadowaki,et al.  Reciprocal control of T helper cell and dendritic cell differentiation. , 1999, Science.

[37]  P. Marrack,et al.  Type I Interferons Keep Activated T Cells Alive , 1999, The Journal of experimental medicine.

[38]  J. Sprent,et al.  Type I Interferon-mediated Stimulation of T Cells by CpG DNA , 1998, Journal of Experimental Medicine.

[39]  M. Biffi,et al.  References Subscriptions Permissions Email Alerts The Role of Stat4 in Species-Specific Regulation of Th Cell Development by Type I , 2013 .

[40]  R. Steinman,et al.  Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. , 1998, Science.

[41]  A. N. Park,et al.  Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells , 1998, Journal of leukocyte biology.

[42]  C. Chastang,et al.  Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.

[43]  S Pestka,et al.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. , 1998, Cancer research.

[44]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[45]  F. Belardelli,et al.  The neglected role of type I interferon in the T-cell response: implications for its clinical use. , 1996, Immunology today.

[46]  J. Stockman.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2010 .

[47]  Yong‐jun Liu,et al.  IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. , 2005, Annual review of immunology.

[48]  B. Beutler,et al.  Type I interferons (alpha/beta) in immunity and autoimmunity. , 2005, Annual review of immunology.

[49]  B. Beutler,et al.  TYPE I INTERFERONS (/) IN IMMUNITY AND AUTOIMMUNITY , 2005 .

[50]  A. Krieg,et al.  CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. , 2003, Journal of immunology.

[51]  I. Kerr,et al.  Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. , 2003, Journal of immunology.

[52]  武田 篤信.  Cutting edge : Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment , 2003 .

[53]  F. Belardelli,et al.  Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. , 2003, Journal of immunology.

[54]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[55]  H. Tilg,et al.  Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients. , 1999, Lancet.

[56]  C. Chastang,et al.  Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. , 1998, Lancet.

[57]  B. Rouse,et al.  The role of T cell immunity in control of herpes simplex virus. , 1992, Current topics in microbiology and immunology.

[58]  E. Proietti,et al.  Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors , 1983, The Journal of experimental medicine.